Literature DB >> 6847855

Evaluation of ileal function using 23-selena-25-homotaurocholate, a-gamma-labeled conjugated bile acid. Initial clinical assessment.

H Nyhlin, M V Merrick, M A Eastwood, W G Brydon.   

Abstract

23-Selena-25-homotaurocholate is a synthetic bile acid labeled with a gamma-ray-emitting radioisotope 75Se. It is readily measured using external detectors and is thus suitable for whole-body counting. Whole-body retention was measured at 0, 4, and 7 days after oral administration to normal controls and to patients with disease of the small intestine, colon, or ileocecal region. Whole-body retention of less than 25% of the administered radioactivity within 4 days is definitely abnormal, but there was overlap between normal and abnormal groups at this time. At 7 days, whole-body retention less than 12% is abnormal and greater than 19% is normal. Between these limits, values may represent minimal ileal dysfunction not demonstrable by older techniques. Excretion of 23-selena-25-homotaurocholate follows a biexponential curve. The faster component has a half-life similar to that of natural bile acid. It is uncertain whether the slower component represents a hitherto unrecognized slowly turning over pool of bile acid or is a metabolic product of 23-selena-25-homotaurocholate not yet identified in vitro. There is a significant relationship between the whole-body retention of 23-selena-25-homotaurocholate and total fecal and primary bile acids. 23-selena-25-homotaurocholate is simple and acceptable for investigating ileal function.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6847855

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  16 in total

1.  Pharmacogenetics of the effects of colesevelam on colonic transit in irritable bowel syndrome with diarrhea.

Authors:  Banny S Wong; Michael Camilleri; Paula J Carlson; Suwebatu Odunsi-Shiyanbade; Sanna McKinzie; Irene Busciglio; Duane Burton; Alan R Zinsmeister
Journal:  Dig Dis Sci       Date:  2012-01-21       Impact factor: 3.199

2.  Ileal absorption of bile acids in patients with chronic cholestasis: SeHCAT test results and effect of ursodeoxycholic acid (UDCA).

Authors:  O Chazouillères; P Marteau; M Haniche; R Jian; R Poupon
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

3.  Scintigraphic evaluation of enterogastric reflux using 75Se-HCAT: methodology and first clinical observations.

Authors:  A Furno; G Sciarretta; G Fagioli; R Pozzato; P Malaguti
Journal:  Eur J Nucl Med       Date:  1987

4.  Biliary lipid composition in idiopathic bile acid malabsorption.

Authors:  M Fracchia; S Pellegrino; P Secreto; A Pera; G Galatola
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

5.  Bile acid malabsorption in Crohn's disease and indications for its assessment using SeHCAT.

Authors:  H Nyhlin; M V Merrick; M A Eastwood
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

6.  Intestinal bile acid malabsorption in cystic fibrosis.

Authors:  S O'Brien; H Mulcahy; H Fenlon; A O'Broin; M Casey; A Burke; M X FitzGerald; J E Hegarty
Journal:  Gut       Date:  1993-08       Impact factor: 23.059

Review 7.  Bile acid malabsorption in chronic diarrhea: pathophysiology and treatment.

Authors:  Alan N Barkun; Jonathan Love; Michael Gould; Henryk Pluta; Hillary Steinhart
Journal:  Can J Gastroenterol       Date:  2013-11       Impact factor: 3.522

8.  Bile acid malabsorption as a cause of chronic diarrhea: diagnostic value of 7alpha-hydroxy-4-cholesten-3-one in serum.

Authors:  G H Sauter; W Münzing; C von Ritter; G Paumgartner
Journal:  Dig Dis Sci       Date:  1999-01       Impact factor: 3.199

9.  75Se HCAT test in the detection of bile acid malabsorption in functional diarrhoea and its correlation with small bowel transit.

Authors:  G Sciarretta; G Fagioli; A Furno; G Vicini; L Cecchetti; B Grigolo; A Verri; P Malaguti
Journal:  Gut       Date:  1987-08       Impact factor: 23.059

10.  Measurement of bile acid half-life using [75Se]HCAT in health and intestinal diseases. Comparison with [75Se]HCAT abdominal retention methods.

Authors:  R Ferraris; G Galatola; A Barlotta; R Pellerito; M Fracchia; F Cottino; M de la Pierre
Journal:  Dig Dis Sci       Date:  1992-02       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.